KB-1164

SGNB7H4V-hIgG1

×
Please enable JavaScript in your browser to complete this form.
12173
Home » SGNB7H4V-hIgG1

Background of SGNB7H4V-hIgG1

SGN-B7H4V, being developed by Seagen, is composed of a fully human IgG1 anti-B7-H4 monoclonal antibody (mAb) conjugated to the microtubule disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable peptide linker. SGN-B7H4V is designed to bind and internalize the immune checkpoint ligand B7-H4/ADC complex from the surface of malignant cells and release the cytotoxic payload MMAE.

Specifications

Catalog NumberKB-1164
Antibody NameSGNB7H4V-hIgG1
IsotypeHuman IgG1,kappa
FC MuationsWild Type
TargetB7H4
Species ReactivityHuman
Host Cell LineEXPI CHO
Purification MethodAffinity purified
Concentration>2 mg/mL
Formulation50 mM sodium citrate,150mM NaCl,pH5.5
Purity>95% by SDS-PAGE and SEC-HPLC
ValidationELISA, FACS, in vivo studies
Endotoxin Level<0.2 EU/mg as determined by the LAL method
Sterility0.2μm filtered
StorageIt is recommended that the protein should be aliquoted for optimal storage.
Avoid repeated freeze-thaw cycles.
StabilityStable for twelve months from date of receipt when stored at -20°C to -80°C;
Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Gray E, Epp A, Ulrich M, et al 854 SGN-B7H4V, a novel, investigational vedotin antibody-drug conjugate directed to the T cell checkpoint ligand B7-H4, shows promising activity in preclinical models. Journal for ImmunoTherapy of Cancer 2021;9:doi: 10.1136/jitc-2021-SITC2021.854
Please enable JavaScript in your browser to complete this form.